Biomarkers of premature atherosclerosis

Trends in Molecular Medicine

Volumn 15, Issue 7, 2009, Pages 323-332

  Kampoli, Anna Maria ^a   Tousoulis, Dimitris ^a   Antoniades, Charalambos ^a   Siasos, Gerasimos ^a   Stefanadis, Christodoulos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ASCORBIC ACID; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYCLIC GMP DEPENDENT PROTEIN KINASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FIBRINOGEN; FLAVONOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITROUS OXIDE; PROTEIN KINASE B; PROTEIN KINASE C;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; ENDOTHELIAL DYSFUNCTION; HUMAN; LIFESTYLE MODIFICATION; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SMOKING; UPREGULATION;

ANIMALS; APOLIPOPROTEINS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CYTOKINES; HUMANS;

EID: 67649874769     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2009.06.001     Document Type: Review

References (83)

1. Daly C.A., et al. Adverse prognosis associated with the metabolic syndrome in established coronary artery disease: data from the EUROPA trial. Heart 93 (2007) 1406-1411
2. Cooper R., et al. Trends and disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States: Findings of the National Conference on Cardiovascular Disease Prevention. Circulation 102 (2000) 3137-3147
3. Virani S.S., et al. Novel markers of inflammation in atherosclerosis. Curr. Atheroscler. Rep. 10 (2008) 164-170
4. Montagnana M., et al. Role of biochemical risk factors and markers for the risk of atherosclerosis. Recenti Prog. Med. 99 (2008) 215-222
5. Davignon J., and Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 109 suppl 1 (2004) III27-III32
6. Feletou M., and Vanhoutte P. Endothelial dysfunction: a multifaceted disorder. Am. J. Physiol. Heart Circ. Physiol. 291 (2006) H985-H1002
7. Landmesser U., et al. Endothelial function: a critical determinant in atherosclerosis?. Circulation 109 (2004) II27-II33
8. Makimattila S., et al. Hyperreactivity to nitrovasodilators in forearm vasculature is related to autonomic dysfunction in insulin-dependent diabetes mellitus. Circulation 95 (1997) 618-625
9. Anderson T.J., et al. Endothelium-dependent coronary vasomotion relates to the susceptibility of LDL to oxidation in humans. Circulation 93 (1996) 1647-1650
10. John S., et al. Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients. A randomized, placebo-controlled, double-blind study. Circulation 98 (1998) 211-216
11. Keaney J.F. Oxidative stress and the vascular wall: NADPH oxidases take center stage. Circulation 112 (2005) 2585-2588
12. Sweet M.J., and Hume D.A. CSF-1 as a regulator of macrophage activation and immune responses. Arch. Immunol. Ther. Exp. (Warsz.) 51 (2003) 169-177
13. Singh U., et al. Vitamin E, oxidative stress and inflammation. Annu. Rev. Nutr. 25 (2005) 151-174
14. Metcalf D. Hematopoietic cytokines. Blood 111 (2008) 485-491
15. Witzum J.L., and Steinberg D. Role of oxidized low-density lipoprotein in atherogenesis. J. Clin. Invest. 88 (1991) 1785-1792
16. Stocker R., and Keaney Jr. J.F. Role of oxidative modifications in atherosclerosis. Physiol. Rev. 84 (2004) 1381-1478
17. Berliner J.A., et al. Atherosclerosis: Basic mechanisms: oxidation, inflammation and genetics. Circulation 91 (1995) 2488-2496
18. Murphy P.M. International Union of Pharmacology. XXX. Update on chemokine receptor nomenclature. Pharmacol. Rev. 54 (2002) 227-229
19. Tsao P.S., et al. Nitric oxide regulates monocyte chemotactic protein-1. Circulation 96 (1997) 934-940
20. Rajavashisth T., et al. Heterozygous osteopetrotic (op) mutation reduces atherosclerosis in LDL receptor-deficient mice. J. Clin. Invest. 101 (1998) 2702-2710
21. Simonini A., et al. IL-8 is an angiogenic factor in human coronary atherectomy tissue. Circulation 101 (2000) 1519-1526
22. Tintut Y., et al. Tumor necrosis factor-α promotes in vitro calcification of vascular cells via the cAMP pathway. Circulation 102 (2000) 2636-2642
23. Ihling C., et al. Coexpression of endothelin-converting enzyme-1 and endothelin-1 in different stages of human atherosclerosis. Circulation 104 (2001) 864-869
24. Mathew V., et al. Enhanced endothelin-mediated coronary vasoconstriction and attenuated basal nitric oxide activity in experimental hypercholesterolemia. Circulation 96 (1997) 1930-1936
25. Iiyama K., et al. Patterns of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 expression in rabbit and mouse atherosclerotic lesions and at sites predisposed to lesion formation. Circ. Res. 85 (1999) 199-207
26. Cybulsky M.I., et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J. Clin. Invest. 107 (2001) 1255-1262
27. Malik I., et al. Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis. Lancet 358 (2001) 971-976
28. Dong Z.M., et al. Prominent role of P-selectin in the development of advanced atherosclerosis in apoE-deficient mice. Circulation 101 (2000) 2290-2295
29. Tousoulis D., et al. Vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 serum level in patients with chest pain and normal coronary arteries (syndrome X). Clin. Cardiol. 24 (2001) 301-304
30. Tentolouris C., et al. The impact of risk factors for atherosclerosis on the vasomotor effects of inhibition of nitric oxide synthesis in patients with normal angiograms. Cardiology 94 (2000) 26-30
31. -/- mice through release of interferon-gamma. Circ. Res. 90 (2002) e34-e38
32. Mehta J.L., et al. Interactive role of infection, inflammation and traditional risk factors in atherosclerosis and coronary artery disease. J. Am. Coll. Cardiol. 31 (1998) 1217-1225
33. Pearson T.A., et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107 (2003) 499-511
34. Koenig W., et al. C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation 109 (2004) 1349-1353
35. Cushman M., et al. C-reactive protein and the 10-year incedence of coronary heart disease in older men and women: the cardiovascular health study. Circulation 112 (2005) 25-31
36. Ridker P.M., et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N. Engl. J. Med. 347 (2002) 1557-1565
37. Chen J., et al. C-reactive protein upregulates receptor for advanced glycation end products expression and alters antioxidant defenses in rat endothelial progenitor cells. J. Cardiovasc. Pharmacol. 53 (2009) 359-367
38. Bo M., et al. High-sensitivity C-reactive protein is not independently associated with peripheral subclinical atherosclerosis. Angiology 60 (2009) 12-20
39. Lorenz M.W., et al. High-sensitivity C-reactive protein is not associated with carotid intima-media progression: the carotid atherosclerosis progression study. Stroke 38 (2007) 1774-1779
40. Ruan X.Z., et al. Mechanisms of dysregulation of low-density lipoprotein receptor expression in vascular smooth muscle cells by inflammatory cytokines. Arterioscler. Thromb. Vasc. Biol. 26 (2006) 1150-1155
41. Dinarello C.A. Interleukin 1 and interleukin 18 as mediators of inflammation and the aging process. Am. J. Clin. Nutr. 83 (2006) 447S-455S
42. Chamberlain J., et al. Interleukin-1 regulates multiple atherogenic mechanisms in response to fat feeding. PLoS One 4 (2009) e5073
43. Ozeren A., et al. Levels of serum IL-1β, IL-2, IL-8 and tumor necrosis factor-α in patients with unstable angina pectoris. Mediators Inflamm. 12 (2003) 361-365
44. Simon A.D., et al. Circulating levels of IL-1β, a prothrombotic cytokine, are elevated in unstable angina versus stable angina. J. Thromb. Thrombolysis 9 (2000) 217-222
45. Hastings N.E., et al. Human IL-8 regulates smooth muscle cell VCAM-1 expression in response to endothelial cells exposed to atheroprone flow. Arterioscler. Thromb. Vasc. Biol. 29 (2009) 725-731
46. Yudkin J.S., et al. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?. Atherosclerosis 148 (2000) 209-214
47. Marques-Vidal P., et al. Prevalence of insulin resistance syndrome in southwestern France and its relationship with inflammatory and hemostatic markers. Diabetes Care 25 (2002) 1371-1377
48. Festa A., et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102 (2000) 42-47
49. Cesari M., et al. Inflammatory markers and cardiovascular disease (The Health, Aging and Body Composition [Health ABC] Study). Am. J. Cardiol. 92 (2003) 522-528
50. Thakore A.H., et al. Association of multiple inflammatory markers with carotid intimal medial thickness and stenosis (from the Framingham Heart Study). Am. J. Cardiol. 99 (2007) 1598-1602
51. Naya M., et al. Plasma interleukin-6 and tumor necrosis factor-α can predict coronary endothelial dysfunction in hypertensive patients. Hypertens. Res. 30 (2007) 541-548
52. Sun J., et al. Mast cells promote atherosclerosis by releasing proinflammatory cytokines. Nat. Med. 13 (2007) 719-724
53. Alizadeh Dehnavi R., et al. Elevated CRP levels are associated with increased carotid atherosclerosis independent of visceral obesity. Atherosclerosis 200 (2008) 417-423
54. Zieske A.W., et al. Elevated serum C-reactive protein levels and advanced atherosclerosis in youth. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 1237-1243
55. Nylaende M., et al. Markers of vascular inflammation are associated with the extent of atherosclerosis assessed as angiographic score and treadmill walking distances in patients with peripheral arterial occlusive disease. Vasc. Med. 11 (2006) 21-28
56. Walldius G., et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 358 (2001) 2026-2033
57. Yusuf S., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364 (2004) 937-952
58. Tousoulis D., et al. Effects of combined administration of vitamins C and E on reactive hyperemia and inflammatory process in chronic smokers. Atherosclerosis 170 (2003) 261-267
59. Benn M., et al. Improving prediction of ischemic cardiovascular disease in the general population using apolipoprotein B: the Copenhagen City Heart Study. Arterioscler. Thromb. Vasc. Biol. 27 (2007) 661-670
60. Benn, M. Apolipoprotein B levels, APOB alleles, and risk of ischemic cardiovascular disease in the general population, a review. Atherosclerosis DOI:10.1016/j.atherosclerosis.2009.01.004.
61. Packard C.J., et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 343 (2000) 1148-1155
62. Ballantyne C.M., et al. Lipoprotein-associated phospholipase A2, high- sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 109 (2004) 837-842
63. Oei H.H., et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: The Rotterdam Study. Circulation 111 (2005) 570-575
64. Tsimikas S., et al. Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study. Eur. Heart J. 30 (2009) 107-115
65. Ernst E., and Resch K.L. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann. Intern. Med. 118 (1993) 956-963
66. Stec J.J., et al. Association of fibrinogen with cardiovascular risk factors and cardiovascular disease in the Framingham offspring population. Circulation 102 (2000) 1634-1638
67. Folsom A.R., et al. Prospective study of hemostatic factors and incidence of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 96 (1997) 1102-1108
68. Danesh J., et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. J. Am. Med. Assoc. 294 (2005) 1799-1809
69. Rizzo M., et al. Markers of inflammation are strong predictors of subclinical and clinical atherosclerosis in women with hypertension. Coron. Artery Dis. 20 (2009) 15-20
70. Jacquemin B., et al. Common genetic polymorphisms and haplotypes of fibrinogenα, β, and γ chains affect fibrinogen levels and the response to proinflammatory stimulation in myocardial infarction survivors: the AIRGENE study. J. Am. Coll. Cardiol. 52 (2008) 941-952
71. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. J. Am. Med. Assoc. 288 (2002) 2015-2022
72. Matetzky S., et al. Association of elevated homocysteine levels with a higher risk of recurrent coronary events and mortality in patients with acute myocardial infarction. Arch. Intern. Med. 163 (2003) 1933-1937
73. Soinio M., et al. Elevated plasma homocysteine level is an independent predictor of coronary heart disease events in patients with type 2 diabetes mellitus. Ann. Intern. Med. 140 (2004) 94-100
74. Tousoulis D., et al. Cold pressor test as a marker for the detection of early stage coronary coronary atherosclerosis. Int. J. Cardiol. 115 (2007) 120-122
75. Antoniades C., et al. Asymmetrical dimethylarginine regulates endothelial function in methionine-induced but not in chronic homocystinemia in humans: effect of oxidative stress and proinflammatory cytokines. Am. J. Clin. Nutr. 84 (2006) 781-788
76. Su J., et al. Wei Sheng Yan Jiu 38 (2009) 43-46
77. Jakubowski H., et al. The pathophysiological hypothesis of homocysteine thiolactone-mediated vascular disease. J. Physiol. Pharmacol. 59 (2008) 155-167
78. -/- mice ex vivo. J. Magn. Reson. Imaging 20 (2004) 981-989
79. Alp N.J., et al. Tetrahydrobiopterin-dependent preservation of nitric oxide-mediated endothelial function in diabetes by targeted transgenic GTP-cyclohydrolase I overexpression. J. Clin. Invest. 112 (2003) 725-735
80. Li Y., et al. Effect of aging on fatty streak formation in a diet-induced mouse model of atherosclerosis. J. Vasc. Res. 45 (2008) 205-210
81. Hofmann M.A., et al. Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. J. Clin. Invest. 107 (2001) 675-683
82. Ridker P.M., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359 (2008) 2195-2207
83. Ridker P.M., et al. Reduction in c-reactive protein and LDL cholesterol and cardiovascular events rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 373 (2009) 1175-1182